Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 7:01 PM
Ignite Modification Date: 2025-12-24 @ 7:01 PM
NCT ID: NCT04581057
Eligibility Criteria: Inclusion Criteria: * Patients (male or female) over 75 years old * Patients with a first CVE (myocardial infarction) of atheromatous origin that occurred between 2 and 7 months before inclusion * Absence of evidence of hematological malignancy (known or obvious by the results of blood counts) * Subject registered with a social security scheme * Written informed consent obtained Exclusion Criteria: * Patients who did not presented any CVE in the last 7 months * Patients with CVE with a non-atheromatous origin (dissection, embolic, …) * Presence of an unbalanced diabetes (defined as HbA1C \> 10%) * History of previous CVE before 75 year-old : myocardial infarction, stroke of atheromatous origin * Hematological malignancy (known or obvious on the results of blood counts) * Chronic inflammatory disease (cancer, vasculitis, rheumatism, hepato-gastro-intestinal diseases). * Long term anti-inflammatory treatments: * Corticoids * Nonsteroidal anti-inflammatory drugs * Aspirin (\> 325 mg per day) * Cyclo-oxygenase II inhibitors * Persons under judicial safeguards, trustee or curators * Person deprived of judicial or administrative freedom * Person unable to give her consent * Non-cooperative person * Exclusion period after another clinical study or participation to another interventional clinical study testing a drug in the 30 days before inclusion
Healthy Volunteers: False
Sex: ALL
Minimum Age: 75 Years
Study: NCT04581057
Study Brief:
Protocol Section: NCT04581057